Stock Overview

Bristol-Myers Squibb Company (BMY)

NYSE · Healthcare · Drug Manufacturers - General

Bristol-Myers Squibb Company is a Healthcare company with a market capitalization of $117.46B, a trailing P/E ratio of 16.1, and a dividend yield of 4.51%.

Market Cap
$117.46B
P/E (TTM)
16.1
Forward P/E
8.8
Price/Sales
2.4
Price/Book
5.6
EV/EBITDA
9.9
Dividend Yield
4.51%
Beta
0.24
EPS (TTM)
$3.57
Profit Margin
15.0%
ROE
38.7%
52W High
$62.25
52W Low
$41.46

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$48.19B
Gross Profit
$32.60B
Operating Income
$12.70B
Net Income
$7.05B
Free Cash Flow
$12.85B
Total Debt
$45.31B
Cash & Equivalents
$10.21B
Shareholder Equity
$18.47B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026April 30, 2026$1.31$1.15+13.9%
Q4 2025February 5, 2026$0.53$0.98-45.9%
Q3 2025October 30, 2025$1.63$1.52+7.2%
Q2 2025July 31, 2025$1.46$1.10+32.7%
Q1 2025April 24, 2025$1.80$1.50+20.0%
Q4 2024February 6, 2025$1.67$1.47+13.6%

Other Drug Manufacturers - General Stocks

Frequently Asked Questions

What is Bristol-Myers Squibb Company's market cap?

As of June 29, 2026, Bristol-Myers Squibb Company (BMY) has a market capitalization of $117.46B.

What is Bristol-Myers Squibb Company's P/E ratio?

Bristol-Myers Squibb Company trades at a trailing price-to-earnings (P/E) ratio of 16.1. Its forward P/E is 8.8.

Does Bristol-Myers Squibb Company pay a dividend?

Yes — Bristol-Myers Squibb Company pays a dividend yielding 4.51%, an annual payout of $2.50 per share.

What sector is BMY in?

Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry.

What was Bristol-Myers Squibb Company's revenue?

In its latest reported fiscal year (ending December 31, 2025), Bristol-Myers Squibb Company reported revenue of $48.19B and net income of $7.05B.

Ask your own questions about BMY

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.